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LETTERS TO THE EDITOR
Single-Nucleotide Polymorphism rs498055
on Chromosome 10q24 Is Not Associated
with Alzheimer Disease in Two Independent
Family Samples
To the Editor: In the January issue of the American Journal
of Human Genetics, Grupe and colleagues1 published evi-
dence suggesting genetic association between SNP rs498055
on chromosome 10q24, located in a putative homologue
of ribosomal protein S3a (RPS3A [MIM 180478]), and risk
for Alzheimer disease (AD [MIM 104300]) in four of six
independent case-control samples. The authors reached
this conclusion after testing nearly 1,400 SNPs, using an
exploratory case-control sample, followed by assessments
of a number of independent data sets of different size,
origin, and ascertainment. Although three of the replica-
tion samples showed significant risk effects for the G allele
of rs498055, this effect was not confirmed in two smaller
series of neuropathologically confirmed AD cases and con-
trols. None of the other 68 “hits” uncovered in the first
pass received the same degree of consistent replication as
did rs498055. Overall, the effect of the putative risk allele
was modest (yielding odds ratios [ORs] between ∼1.3 and
1.4) and—according to the authors’ conclusion—likely re-
flects linkage disequilibrium (LD) with another genetic
variant nearby. Here, we have set out to independently
assess the association between rs498055 and AD risk in
two large and carefully characterized samples of AD-af-
fected families comprising nearly 1,900 subjects from 654
pedigrees. However, in contrast to the findings of Grupe
and colleagues, we observed no evidence of association
between rs498055 and AD in any of our analyses.
Using high-efficiency fluorescence polarization (HEFP)
technology, we genotyped this SNP in two family-based
AD samples: (1) 1,439 subjects from 437 multiplex AD-
affected families recruited as part of the National Institute
of Mental Health (NIMH) Genetics Initiative AD Study
Sample (average age at onset [SD] of affected individuals
was years) and (2) 489 subjects from 217 in-72.4 7.7
dependent families, mostly consisting of discordant sib-
ships, recruited as part of the Consortium on Alzheimer’s
Genetics (CAG) (average age at onset was years).71.29.1
These samples, as well as the genotyping procedures, are
described in detail in the work of Bertram et al.2; PCR and
HEFP primer sequences for rs498055 are available on re-
quest. Average genotyping efficiency across both samples
was 98.4%, with a genotyping error rate !1% (on the basis
of ∼10% duplicated samples). Power analyses (fig. 1) in
the combined sample showed that, at a disease-allele fre-
quency of 0.47 (i.e., the average frequency of the G allele
in U.S. controls reported by Grupe et al.) and ,ap .05
power was 64% for an OR of 1.3 and was 83% for an OR
of 1.4 (see fig. 1 for more details). Naturally, power was
lower for the two samples considered separately, but it was
still 40%–60% for the NIMH sample alone, comparable to
the power of the replication samples in the study byGrupe
et al.
In contrast to the findings of Grupe et al., we did not
observe any significant evidence of association between
rs498055 and AD risk, neither in the two samples indi-
vidually nor after combining both data sets (table 1), over-
all or when stratified by age at onset (with age 65 years
as cutoff) or apolipoprotein E (APOE [MIM 107741]) 4-
carrier status. Interestingly, and in contrast to the over-
transmission of the G allele noted by Grupe et al., in our
two samples, this allele was generally undertransmitted
to affected individuals, which approached statistical sig-
nificance in two of our stratified analyses in the combined
sample ( in “late-onset” families, and inPp .09 Pp .06
“APOE 4-positive” families [table 1]). Finally, we also
tested for association between rs498055 and age at onset
of AD (age at last examination of unaffected individuals),
using FBAT-LOGRANK, FBAT-Wilcoxon, and FBAT-Flem-
ington-Harrington3,4 in the unstratified samples. However,
none of these tests showed even marginally significant P
values (data not shown). Since quantitative trait analyses
are expected to be more powerful than analyses of binary
traits if the underlying association is true,3 these results
strengthen our overall negative conclusion.
Our study is the first to independently assess the poten-
tial association between rs498055 andAD that had emerged
from a semisystematic screen of 1,397 SNPs on chromo-
some 10.1 The fact that we failed to replicate the previous
findings is noteworthy for several reasons. First, rs498055
is located within the chromosome 10q24 linkage peak re-
ported elsewhere for this collection of NIMH families.5
Thus, our sample should be particularly well suited to de-
tect disease associations underlying this linkage signal.
Second, our study is the first to analyze this SNP with use
of family-based methodologies in which affected subjects
are compared with related unaffected subjects from the
same family. Results from such analyses are more robust
to bias due to population admixture or other sources of
skewed genotype distributions in cases or controls; this is
of particular note, given the differences in allele frequen-
cies reported for the two control populations from the St.
Louis area in the work of Grupe et al. (see below). Despite
the strengths of our approach, it is possible that we have
missed a putative risk effect at rs498055 because of insuf-
ficient power, especially when aiming to detect minor ef-
fects with ORs of 1.3 (fig. 1). However, the differences
between our findings and those of Grupe et al. are unlikely
to result from lack of power alone, since we see under-
rather than overtransmission of the G allele in both sam-
ples. It is unclear whether these discrepancies are caused
by chance or by differential patterns of LD across the var-
ious samples.
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Figure 1. Power to detect a range of effect sizes in the family samples analyzed. Power estimates were done with PBAT (v3.1).12
Estimates are based on approximation and are calculated for an additive disease model based on parameters published by Grupe et al.1
(i.e., disease-allele frequency of 0.47 and OR 1.2–1.6), with the exception of disease prevalence, which was set to 10%. Although the
precise prevalence of AD is unknown and difficult to estimate, power does not change appreciably when prevalence is varied from 5%
to 15% (data not shown). ORs are for heterozygous carriers of the disease allele versus homozygous noncarriers. Families were modeled
after the observed pedigree structure for each sample, with both parents set as “missing.” Note that PBAT can currently handle a
maximum offspring number of only four; however, 68 (16%) of NIMH pedigrees actually have more than four genotyped and phenotyped
offspring, so that the power for “NIMH” and “NIMHCAG” is likely to be underestimated (see the PBAT Web site for more details).
The long arm of chromosome 10 has been a focus of
work formany AD genetics laboratories since thediscovery
of significant linkage with AD phenotypes by three inde-
pendent groups, including ours (AD6 [MIM 605526]).5–7
These publications were followed by two additional stud-
ies suggesting the presence of an AD risk and/or age-at-
onset–modifying gene on this chromosome.8,9 Although
nearly 30 positional candidate genes have since been as-
sessed as potential AD risk factors underlying these linkage
signals and several positive association findings have been
published, no gene has received consistent support from
independent follow-up studies,10 and none shows evidence
of conclusive and significant summary effects in system-
atic meta-analyses of all published and available genotype
data (AlzGene).
Unfortunately, the present failure to replicate the prom-
ising results of Grupe and colleagues is consistent with
this overall pattern. There are several possible reasons for
the differences between our findings and theirs. First, the
differencemight be due to chance, because the initial find-
ing is a false-positive result. The 69 hits among 1,397 SNPs
in the exploratory data set is close to the expected value
by chance alone, as is the confirmation of 5 of these 69
signals in at least one of the two direct follow-up samples.
However, we agree with the authors that a significant over-
representation of the same allele in three of five confir-
mation samples, as observed for rs498055,may be unlikely
to occur by chance alone. Second, the difference might
have arisen by chance because our finding is a false-neg-
ative result. Although this is possible, it should be noted
that our sample is as large or larger than many replication
samples in the field. In addition, the difference is unlikely
to result from insufficient power alone, because the puta-
tive risk allele, if anything, is undertransmitted in our sam-
ples. Third, the differences may relate to our use of family-
based methods, which are more robust to bias due to pop-
ulation admixture. Although the degree to which admix-
ture may lead to spurious association findings in case-
control samples is controversial,11 the issue is a concern
here, given the marked difference in allele frequencies
across the two independent Washington University con-
trol samples (47% for the case-control sample—similar to
the other U.S. control sample—and 44% for the controls
used in comparison with the linkage sample), a difference
substantial enough that the allelic association between
rs498055 and AD in the linkage sample (49.8% risk-allele
frequency) would not have been significant had the other
Washington University control set (or the University of
California–San Diego controls) been used. Finally, the dif-
ferences across studies may be due to differences in pat-
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Table 1. Association Analyses of rs498055 in Two Independent Family
Samples
Samplea
FBAT Statistic Result
G Allele
Frequency
No. of Informative
Families
Z
Scoreb P
All Families:
NIMH .519 123 1.096 .27
CAG .504 84 .194 .85
Combined .514 207 1.001 .32
Families with late-onset disease:
NIMH .537 81 1.541 .12
CAG .531 66 .808 .42
Combined .535 147 1.703 .09
APOE 4-positive families:
NIMH .494 107 1.488 .14
CAG .515 31 1.380 .17
Combined .499 138 1.929 .06
NOTE.—Association tests were performed using FBAT (v1.5.5) with an additive transmission
model, the empirical variance function, and an equal-weight offset correction for affected and
unaffected individuals (see the FBAT Web site for more details).
a Families were classified as “late onset” when all sampled affected individuals had age at
onset of 165 years and were classified as “APOE 4 positive” when at least one affected individual
per family carried the 4 allele. The smaller strata of remaining families (i.e., those displaying
an earlier age at onset or those in which none of the affected individuals carried an 4 allele)
also failed to show evidence of significant association (data not shown).
b For the G allele of rs498055, which was reported as the putative risk allele by Grupe et al.1
(positive values indicate overtransmission to affected individuals). Note that the direction of
transmission is consistent for both family samples analyzed here and is opposite to that seen
in the previous publication.1
terns of LD across the various samples, which are impos-
sible to assess as long as the precise nature of the putative
risk allele at this locus remains unknown.
Clearly, additional analyses of sufficiently powered
and independent samples are needed to assert whether
rs498055, or a polymorphism in LD with it, makes a rel-
evant contribution to AD risk. At least in the two family
samples investigated here—one of which shows linkage
to the same chromosomal interval as rs498055—this SNP
is not a major determinant of AD risk.
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Reply to Bertram et al.
To the Editor: The study by Bertram and colleagues (in
this issue)1 failed to replicate, in two family-based sample
sets, the association of rs498055 with Alzheimer disease
(AD [MIM 104300]) that we observed in four large, well-
characterized case-control sample sets.2 Although the re-
sult is disappointing, there are several differences between
the studies that may have contributed to these discrepant
findings. First, there are significant differences in the study
designs. Bertram et al. used two family-based sample sets
that included subjects with both early- and late-onset
AD (e.g., 320 families with late-onset AD and 117 families
with early/mixed-onset in the National Institute ofMental
Health [NIMH] sample set) of different ethnicities (94%
white; 6% others),3 which resulted in 147 informative
families with late-onset AD for both sample sets com-
bined. The characterization of their unaffected controls
was based on self-assessment or a telephone interview, a
procedure sufficient when “unaffecteds” are used solely
to determine phase in linkage studies, but likely to sig-
nificantly impact power in association studies, especially
when familial loading is high, as it is in the sample of
Bertram et al. Indeed, the authors acknowledge this in one
of their previous publications by pointing out that the
characterization of controls “may miss some mild cases of
dementia” and lead “to a decrease in power.”3 In contrast,
our study included only clinically evaluated, late-onset
cases and nondemented controls of white origin. Second,
the use of a family-based sample that was ascertained on
the basis of multiple affected relatives is likely to partic-
ularly adversely impact power to detect a risk allele of
relatively high frequency and small effect size, such as
rs498055. Under these circumstances, the allele frequency
in unaffected relatives also increases,4 with consequent
loss of power in comparisonwith case-control studies such
as our own. To investigate this more fully, we compared
the allele frequencies for a known genetic risk factor for
AD, apolipoprotein E (APOE [MIM 107741]), and for the
putative risk factor under debate, rs498055, in our com-
bined case-control series and in the NIMH linkage families
used by us in the study described by Myers et al.5 In this
context, it is worth noting that 355 of 372 individuals
from the linkage sample–derived cases in our recent pub-
lication overlap with affected individuals in the NIMH
family sample set described by Bertram et al. For the com-
parison, we identified the subgroup of NIMH families with
genotypes for at least one unaffected and one affected
individual and then selected at random one unaffected
and one affected individual from each of these families.
Table 1 illustrates clearly that the frequency of the APOE4
allele is substantially higher in unaffected individuals from
the linkage families than in unaffected individuals from
the case-control series (30.4% vs. 12.5%) and that, although
the APOE4 allele frequency is highest in the linkage cases,
the difference between the unrelated cases and controls
is much greater than that between familial cases and re-
lated controls (35.6% vs. 12.5% compared with 42.8% vs.
30.4%). As a result, the odds ratio (OR) for theAPOE4 allele
in the case-control series is 3.8, compared with only 1.7
